Literature DB >> 36106070

A novel pyroptosis-related gene signature for predicting laryngeal carcinoma prognosis.

Haopeng Zhang1, Lihua Wang1, Ziming Yin2, Lin Ji1, Yu Guo1.   

Abstract

Pyroptosis, a newly-defined mode of cell death related to inflammation, is closely related to cancers but has not yet been studied in laryngeal carcinoma (LC). We investigated pyroptosis in LC and constructed a prognostic model. Using RNA sequencing data, we identified differentially expressed genes (DEGs) in LC and normal tissues to construct a prognostic risk model. The model's accuracy and independent prognostic value were evaluated using survival- and receiver operating characteristic (ROC)- curves; and univariate and multivariate Cox regression analyses, respectively. Gene Expression Omnibus (GEO) data was utilized as a model validation set. Differential analysis revealed 37 DEGs, and consistent clustering showed that pyroptosis-related genes could predict LC prognosis. Six genes (CHMP7, GSDME, GZMB, CASP9, IL6, and NLRP1) were obtained by Lasso Cox regression analysis to construct a prognostic model. The high-risk group had a poor prognosis with areas under the ROC curve at 1-, 3-, and 5-years of 0.619, 0.692, and 0.656, respectively. Univariate and multivariate Cox analyses showed that the risk score was an independent prognostic factor. Enrichment analysis of GO and KEGG pathways revealed that differentially expressed genes may be related to infection, T cell differentiation, immunity, and inflammation. It was further found that the low survival rate of the high-risk group may be related to the significant reduction of immune cell infiltration and immune function. With the bioinformatic method, six genes related to pyroptosis affecting LC prognosis were screened and a prognostic risk model was constructed, which laid a foundation for pyroptosis study in LC. IJCEP
Copyright © 2022.

Entities:  

Keywords:  Lasso Cox regression; Pyroptosis; gene expression; laryngeal carcinoma; prognosis

Year:  2022        PMID: 36106070      PMCID: PMC9441861     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  39 in total

Review 1.  The NLRP1 inflammasomes.

Authors:  Joseph Chavarría-Smith; Russell E Vance
Journal:  Immunol Rev       Date:  2015-05       Impact factor: 12.988

Review 2.  An update on larynx cancer.

Authors:  Conor E Steuer; Mark El-Deiry; Jason R Parks; Kristin A Higgins; Nabil F Saba
Journal:  CA Cancer J Clin       Date:  2016-11-29       Impact factor: 508.702

Review 3.  CHMPions of repair: Emerging perspectives on sensing and repairing the nuclear envelope barrier.

Authors:  C Patrick Lusk; Nicholas R Ader
Journal:  Curr Opin Cell Biol       Date:  2020-02-24       Impact factor: 8.382

Review 4.  The changing therapeutic landscape of head and neck cancer.

Authors:  John D Cramer; Barbara Burtness; Quynh Thu Le; Robert L Ferris
Journal:  Nat Rev Clin Oncol       Date:  2019-06-12       Impact factor: 66.675

Review 5.  Treatment of early-stage laryngeal cancer: A comparison of treatment options.

Authors:  Brandon Jackson Baird; C Kwang Sung; Beth M Beadle; Vasu Divi
Journal:  Oral Oncol       Date:  2018-10-16       Impact factor: 5.337

6.  Regulatory T Cells Restrain Interleukin-2- and Blimp-1-Dependent Acquisition of Cytotoxic Function by CD4+ T Cells.

Authors:  Anna Śledzińska; Maria Vila de Mucha; Katharina Bergerhoff; Alastair Hotblack; Dafne Franz Demane; Ehsan Ghorani; Ayse U Akarca; Maria A V Marzolini; Isabelle Solomon; Frederick Arce Vargas; Martin Pule; Masahiro Ono; Benedict Seddon; George Kassiotis; Charlotte E Ariyan; Thomas Korn; Teresa Marafioti; Graham M Lord; Hans Stauss; Richard G Jenner; Karl S Peggs; Sergio A Quezada
Journal:  Immunity       Date:  2020-01-07       Impact factor: 31.745

7.  Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling.

Authors:  Chuanhui Han; Zhida Liu; Yunjia Zhang; Aijun Shen; Chunbo Dong; Anli Zhang; Casey Moore; Zhenhua Ren; Changzheng Lu; Xuezhi Cao; Chun-Li Zhang; Jian Qiao; Yang-Xin Fu
Journal:  Nat Immunol       Date:  2020-03-30       Impact factor: 25.606

8.  Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis.

Authors:  Dan A Erkes; Weijia Cai; Ileine M Sanchez; Timothy J Purwin; Corey Rogers; Conroy O Field; Adam C Berger; Edward J Hartsough; Ulrich Rodeck; Emad S Alnemri; Andrew E Aplin
Journal:  Cancer Discov       Date:  2019-12-03       Impact factor: 38.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.